Biogen

Biogen Net Income

The Net Income of Biogen (BIIB) as of Nov 6, 2026 is 1.29 B USD. In the previous year, Net Income was 1.63 B USD — a change of -20.79% (lower).

Net Income

1.29 BUSD

YoY

-20.79%

Last updated:

In 2025, Biogen's profit amounted to 1.29 B USD, a -20.79% increase from the 1.63 B USD profit recorded in the previous year.

The Biogen Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2024
1.63 B USD
Jan 1, 2025
1.29 B USD
Jan 1, 2026 (e)
1.83 B USD
Jan 1, 2027 (e)
2.39 B USD
Jan 1, 2028 (e)
2.71 B USD
Jan 1, 2029 (e)
2.99 B USD
Jan 1, 2030 (e)
3.07 B USD
Jan 1, 2031 (e)
2.72 B USD
The Biogen Net Income history
YEARNet IncomeYoY
est2.72 BUSD-11.57%
est3.07 BUSD+2.87%
est2.99 BUSD+10.32%
est2.71 BUSD+13.22%
est2.39 BUSD+30.54%
est1.83 BUSD+41.64%
1.29 BUSD-20.79%
1.63 BUSD+40.57%
1.16 BUSD-61.89%
3.05 BUSD+95.82%
1.56 BUSD-61.11%
4.00 BUSD-32.06%
5.89 BUSD+32.90%
4.43 BUSD+74.52%
2.54 BUSD-31.43%
3.70 BUSD+4.40%
3.55 BUSD+20.85%
2.94 BUSD+57.63%
1.86 BUSD+34.93%
1.38 BUSD+11.83%
1.23 BUSD+23.03%
1.00 BUSD+3.62%
968.00 MUSD+23.79%
782.00 MUSD+22.76%
637.00 MUSD+193.55%
217.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biogen Revenue

Biogen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
9.68 B USD
2.65 B USD
1.63 B USD
Jan 1, 2025
9.89 B USD
2.79 B USD
1.29 B USD
Jan 1, 2026 (e)
10.55 B USD
2.33 B USD
1.83 B USD
Jan 1, 2027 (e)
10.76 B USD
2.99 B USD
2.39 B USD
Jan 1, 2028 (e)
11.10 B USD
3.34 B USD
2.71 B USD
Jan 1, 2029 (e)
11.40 B USD
3.63 B USD
2.99 B USD
Jan 1, 2030 (e)
11.60 B USD
3.73 B USD
3.07 B USD
Jan 1, 2031 (e)
9.55 B USD
0.00 USD
2.72 B USD

Biogen Margins

Biogen stock margins

The Biogen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biogen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biogen.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
77.18 %
27.40 %
16.87 %
Jan 1, 2025
75.99 %
28.23 %
13.07 %
Jan 1, 2026 (e)
75.99 %
22.08 %
17.36 %
Jan 1, 2027 (e)
75.99 %
27.84 %
22.22 %
Jan 1, 2028 (e)
75.99 %
30.10 %
24.38 %
Jan 1, 2029 (e)
75.99 %
31.89 %
26.20 %
Jan 1, 2030 (e)
75.99 %
32.17 %
26.48 %
Jan 1, 2031 (e)
75.99 %
0.00 %
28.46 %

Biogen Stock analysis

What does Biogen do? Biogen Inc. is an American biotechnology company specializing in the development, manufacturing, and marketing of therapeutics for neurodegenerative diseases, autoimmune diseases, and hemophilia. The company was founded in 1978 and is a Fortune 500 company headquartered in Cambridge, Massachusetts. It employs over 7,000 employees worldwide. The origins of Biogen can be traced back to its founding by Charles Weissmann, a Swiss biology professor, and American entrepreneurs Walter Gilbert and Phillip Sharp. The company initially focused on the development of interferon, a protein that protects the body against viruses. However, in the late 1980s, Biogen shifted its research and development efforts towards neurodegenerative diseases. Biogen's business model is based on the discovery and development of new and unique treatments for serious diseases. Through research, the discovery of new compounds, as well as acquisitions and partnerships with other companies, Biogen continually expands its product pipeline. The company also has a strong presence in the global market, selling its products in over 90 countries worldwide. Biogen has sought to expand into multiple areas of the biopharmaceutical industry. The company is divided into three main business areas: neurology, immunology, and hemophilia. In the neurology field, Biogen is a leading provider of drugs for the treatment of severe diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. The company has developed several innovative therapeutics that can either slow down or even halt the progression of these diseases. One example is the drug Aduhelm®, which recently gained approval from the US Food and Drug Administration (FDA) for the treatment of Alzheimer's and garnered worldwide attention. In the immunology field, Biogen offers medications for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Biogen is also a major provider of biosimilars, which are replicas of biopharmaceutical drugs developed and manufactured by other companies. Biosimilars can help reduce the cost of patient treatment, particularly in countries with limited healthcare resources. In the hemophilia field, Biogen's offerings include a range of products and services specifically developed for patients with hemophilia. These include clotting factor preparations for the treatment of bleeding, novel clotting factors, and specialized clotting tests. Biogen also invests significantly in the research of new technologies and platforms. The company has formed partnerships with other leading biotech companies such as Ionis Pharmaceuticals and Sangamo Therapeutics to develop innovative technologies like antisense oligonucleotides, genome editing, and gene silencing. Biogen is also a founding member of BioNTech, a German biotechnology company known for its development of mRNA-based vaccines for cancer and infectious diseases. Overall, Biogen has an impressive track record in the development of innovative therapeutics for complex diseases. The company has a strong presence in the global market and aims to expand its product pipeline through research and partnerships. With its high commitment to innovation, Biogen is well-positioned to play a significant role in the biopharmaceutical industry in the future. Biogen is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Biogen's Profit Margins

The profit margins of Biogen represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Biogen's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Biogen's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Biogen's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Biogen’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Biogen stock

Net Income of Biogen is 1.29 B USD in 2025.

Net Income of Biogen changed from 1.63 B USD to 1.29 B USD, representing a -20.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Income Biogen since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Biogen historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biogen

All Key Metrics — Biogen